Samil Pharmaceutical announced on the 14th that its cumulative sales for the third quarter of this year, based on separate standards, reached 161.9 billion KRW, marking an 11.0% increase compared to the same period last year, and operating profit grew by 29.0% to 8.9 billion KRW.
The increase in sales is attributed to steady growth in existing product lineups such as 'Libact' and 'Libidi', as well as recently launched new products like 'Rebakei' and 'Apillibu'. By business division, all divisions including the ETC Sales Headquarters focused on internal medicine, the CNS (Central Nervous System) Sales Headquarters, and the Ophthalmology Sales Headquarters showed balanced growth. Among these, 'Apillibu', a biosimilar of Eylea developed by Samsung Bioepis, recorded a surprising performance with sales of 1 billion KRW in its first month after launching in May and continues to show steady growth.
The CNS (Central Nervous System) division, which has been experiencing rapid growth recently, also achieved cumulative third-quarter sales of 26.9 billion KRW, representing a 28.0% increase compared to the same period last year.
Samil Pharmaceutical's CNS division had sales of 6.7 billion KRW in 2021. However, since the second half of 2021, by forming a dedicated sales team and continuously expanding new psychiatric drug lineups such as Viatris and Sandoz, the division recorded 21.1 billion KRW in 2022 and 28.0 billion KRW in 2023, maintaining rapid growth.
A company representative stated, “Along with steady growth in our core business, we expect additional growth drivers to be secured once the global ophthalmic solution CMO factory begins full-scale operations starting next year.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
